SiSaf

Executive Summary

SiSaf Ltd is a UK-based biopharmaceutical company pioneering RNA therapeutics for cancer and musculoskeletal disorders, leveraging its proprietary Bio-Courier® hybrid silicon-lipid nanoparticle delivery platform. The technology addresses key challenges in nucleic acid delivery, enabling targeted and efficient intracellular transport. Operating out of Guildford with integrated R&D and pilot manufacturing, SiSaf has advanced to Phase 2 clinical development, indicating promising proof-of-concept data. While the company remains private with limited disclosed financials, its platform has the potential to unlock RNA therapeutics for previously undruggable targets. The company’s focus on high unmet medical needs and its novel delivery technology position it as a notable player in the RNA therapy space, though execution risks and competitive pressures remain. Key upcoming catalysts include clinical data readouts, potential strategic partnerships, and financing milestones that could validate its technology and drive valuation.

Upcoming Catalysts (preview)

• H1 2026Phase 2 data readout for lead candidate in oncology40% success
• 2026Partnership/licensing deal for Bio-Courier platform30% success
• 2026Series B or C financing round to fund pipeline50% success